174 related articles for article (PubMed ID: 10180285)
21. Food labeling: health claims; calcium and osteoporosis, and calcium, vitamin D, and osteoporosis. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2008 Sep; 73(189):56477-87. PubMed ID: 18985959
[TBL] [Abstract][Full Text] [Related]
22. Dissemination of information on unapproved/new uses for marketed drugs, biologics, and devices--FDA. Final rule.
Fed Regist; 1998 Nov; 63(224):64556-88. PubMed ID: 10339052
[TBL] [Abstract][Full Text] [Related]
23. Removal of regulations regarding certification of antibiotic drugs; companion document to direct final rule--FDA. Proposed rule.
Fed Regist; 1998 May; 63(91):26127-9. PubMed ID: 10179335
[TBL] [Abstract][Full Text] [Related]
24. Food labeling: health claims; D-tagatose and dental caries. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2003 Jul; 68(128):39831-3. PubMed ID: 12848171
[TBL] [Abstract][Full Text] [Related]
25. Removal of regulations regarding certification of antibiotic drugs--FDA. Direct final rule.
Fed Regist; 1998 May; 63(91):26066-9. PubMed ID: 10179333
[TBL] [Abstract][Full Text] [Related]
26. Food labeling: nutrient content claims, expansion of the nutrient content claim "lean". Final rule.
Food and Drug Administration, HHS
Fed Regist; 2007 Jan; 72(8):1455-9. PubMed ID: 17294560
[TBL] [Abstract][Full Text] [Related]
27. Removal of regulations regarding certification of drugs composed wholly or partly of insulin; companion document to direct final rule--FDA. Proposed rule.
Fed Regist; 1998 May; 63(92):26690-3. PubMed ID: 10179340
[TBL] [Abstract][Full Text] [Related]
28. Removal of regulations regarding certification of drugs composed wholly or partly of insulin--FDA. Direct final rule.
Fed Regist; 1998 May; 63(92):26694-9. PubMed ID: 10179341
[TBL] [Abstract][Full Text] [Related]
29. Regulations for in vivo radiopharmaceuticals used for diagnosis and monitoring--FDA. Proposed rule.
Fed Regist; 1998 May; 63(99):28301-9. PubMed ID: 10179873
[TBL] [Abstract][Full Text] [Related]
30. Administrative practices and procedures; internal agency review of decisions--FDA. Direct final rule; withdrawal.
Fed Regist; 1998 Sep; 63(184):50757. PubMed ID: 10185804
[TBL] [Abstract][Full Text] [Related]
31. Food labeling: health claims; dietary noncariogenic carbohydrate sweeteners and dental caries. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2006 Mar; 71(60):15559-64. PubMed ID: 16572525
[TBL] [Abstract][Full Text] [Related]
32. Food labeling: health claims; dietary noncariogenic carbohydrate sweeteners and dental caries. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2008 May; 73(102):30299-301. PubMed ID: 18605406
[TBL] [Abstract][Full Text] [Related]
33. Human drugs and biologics; determination that informed consent is NOT feasible or is contrary to the best interests of recipients; revocation of 1990 interim final rule; establishment of new interim final rule. Food and Drug Administration, HHS. Interim final rule; opportunity for public comment.
Fed Regist; 1999 Oct; 64(192):54180-9. PubMed ID: 11010702
[TBL] [Abstract][Full Text] [Related]
34. Medical devices; 30-day notices and 135-day PMA supplement review--FDA. Direct final rule; withdrawal.
Fed Regist; 1998 Aug; 63(154):42699. PubMed ID: 10182563
[TBL] [Abstract][Full Text] [Related]
35. Registration of food facilities under the Public Health Security and Bioterrorism Preparedness and Response Act of 2002. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2005 Oct; 70(190):57505-9. PubMed ID: 16200686
[TBL] [Abstract][Full Text] [Related]
36. Medical devices; exemption from premarket notification and reserved devices; class I. Food and Drug Administration, HHS. Final rule.
Fed Regist; 2000 Jan; 65(10):2296-323. PubMed ID: 11010655
[TBL] [Abstract][Full Text] [Related]
37. Postmarketing studies for approved human drug and licensed biological products; status reports. Food and Drug Administration, HHS. Final rule.
Fed Regist; 2000 Oct; 65(210):64607-19. PubMed ID: 11503687
[TBL] [Abstract][Full Text] [Related]
38. Applications for FDA approval to market a dew drug: patent submission and listing requirements and application of 30-month stays on approval of abbreviated new drug applications certifying that a patent claiming a drug is invalid or will not be infringed. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2003 Jun; 68(117):36675-712. PubMed ID: 12814136
[TBL] [Abstract][Full Text] [Related]
39. Food Labeling: Health Claims; Dietary Saturated Fat and Cholesterol and Risk of Coronary Heart Disease. Interim final rule; request for comments.
Food and Drug Administration, HHS
Fed Regist; 2016 Dec; 81(243):91716-22. PubMed ID: 28030885
[TBL] [Abstract][Full Text] [Related]
40. Status of certain additional over-the-counter drug category II and III active ingredients--FDA. Final rule.
Fed Regist; 1998 Apr; 63(77):19799-802. PubMed ID: 10179316
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
